Vaccines are one of the best ways to prevent the world’s most common and dangerous infectious diseases.

Smart Vaccines – a new generation of vaccines

Intercell has specialized in the development of “smart vaccines”, which include only the essential ingredients and which stimulates both sides of the immune system: T-cells and B-cells.

Intercell’s first product on the market is a Japanese Encephalitis vaccine. The product is approved in the U.S. (FDA), Europe (European Commission), Canada (Health Canada) and Australia (TGA).

The vaccine aiming to prevent Pseudomonas is being developed in-house and has shown excellent results in completed clinical trials.

Clostridium difficile is the major cause of nosocomial diarrhea. In 2010, Intercell started a Phase I clinical trial to prevent Clostridium difficile infections.

Our therapeutic vaccine against Hepatitis C has shown statistically significant viral load reduction and an excellent safety profile in completed Phase II trials.

We are developing a Pandemic Influenza vaccine (Phase II) using our groundbreaking vaccine-patch technology.

The vaccine against Tuberculosis (in Phase I/II clinical trials) uses our adjuvant IC31® with antigens from Statens Serum Institut and sanofi-aventis.